- Cutaneous adverse events (AEs) are associated with improved PFS in patients with stage IIIC/IV melanoma treated with PD-1 inhibitor (pembrolizumab or nivolumab).
Why this matters
- This study adds evidence to the model that development of immune-mediated AEs correlates with treatment response to immunotherapy.
- 40.2% of patients experienced ≥1 cutaneous AE (eczema, lichenoid reaction, or vitiligo-like depigmentation).
- Patients who developed ≥1 cutaneous AE had lower risk for disease progression/mortality (HR, 0.460; P=.025) compared with patients who did not.
- This result was also significant in landmark analysis at 6 (HR, 0.45; P=.045) and 12 (HR, 0.35; P=.020) months.
- 82 patients with stage IIIC/IV melanoma treated with pembrolizumab or nivolumab were analyzed for cutaneous AEs and PFS.
- Funding: None.
- Small patient sample size.
- No multivariate analysis.